Parathyroid hormone analogues in the treatment of osteoporosis

Nature Reviews Endocrinology

Volumn 7, Issue 11, 2011, Pages 647-656

  Kraenzlin, Marius E ^a   Meier, Christian ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; GLUCOCORTICOID; IBANDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; ZOLEDRONIC ACID;

BONE DENSITY; BONE MASS; BONE REMODELING; BONE STRENGTH; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE SEVERITY; DRUG COST; DRUG WITHDRAWAL; FRACTURE; FRAGILITY FRACTURE; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; INCIDENCE; MUSCLE CRAMP; NAUSEA; NONHUMAN; OSSIFICATION; OSTEOPOROSIS; OSTEOSARCOMA; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; VERTEBRA FRACTURE;

ANIMALS; BONE DENSITY; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; PARATHYROID HORMONE; TREATMENT OUTCOME;

EID: 80054893464     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.108     Document Type: Review

References (83)

1. Raisz, L. G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Invest. 115, 3318-3325 (2005). (Pubitemid 43121814)
2. Miller, P. D. & Derman, R. J. What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? Osteoporos. Int. 21, 1793-1802 (2010).
3. Reginster, J. Y. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 71, 65-78 (2011).
4. Canalis, E., Giustina, A. & Bilezikian, J. P. Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med. 357, 905-916 (2007).
5. Frolik, C. A. et al. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 33, 372-379 (2003). (Pubitemid 37103254)
6. Kousteni, S. & Bilezikian, J. P. The cell biology of parathyroid hormone in osteoblasts. Curr. Osteoporos. Rep. 6, 72-76 (2008).
7. Bauer, W., Aub, J. C. & Albright, F. Studies of calcium and phosphorus metablism: V. A study of the bone trabeculae as readily available reserve supply of calcium. J. Exp. Med. 49, 145-162 (1929).
8. Reeve, J. et al. Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet 1, 1035-1038 (1976).
9. Reeve, J., Tregear, G. W. & Parsons, J. A. Preliminary trial of low doses of human parathyroid hormone 1-34 peptide in treatment of osteoporosis. Calcif. Tissue Res. 21 (Suppl.), 469-477 (1976).
10. Reeve, J. et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br. Med. J. 280, 1340-1344 (1980). (Pubitemid 10124272)
11. Habener, J. F., Rosenblatt, M. & Potts, J. T. Jr. Parathyroid hormone: biochemical aspects of biosynthesis, secretion, action, and metabolism. Physiol. Rev. 64, 985-1053 (1984). (Pubitemid 14084549)
12. Mosekilde, L., Søgaard, C. H., Danielsen, C. C., Tørring, O. & Nilsson, M. H. The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH (1-34) and hPTH (1-84). Endocrinology 129, 421-428 (1991).
13. Yang, D., Guo, J., Divieti, P. & Bringhurst, F. R. Parathyroid hormone activates PKC-delta and regulates osteoblastic differentiation via a PLC-independent pathway. Bone 38, 485-496 (2006).
14. Silver, J. & Bushinsky, D. Harnessing the parathyroids to create stronger bones. Curr. Opin. Nephrol. Hypertens. 13, 471-476 (2004). (Pubitemid 38901628)
15. Swarthout, J. T., D'Alonzo, R. C., Selvamurugan, N. & Partridge, N. C. Parathyroid hormone-dependent signaling pathways regulating genes in bone cells. Gene 282, 1-17 (2002). (Pubitemid 34117557)
16. Jilka, R. L., O'Brien, C. A., Bartell, S. M., Weinstein, R. S. & Manolagas, S. C. Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms. J. Bone Miner. Res. 25, 2427-2437 (2010).
17. Gatti, D. et al. The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J. Clin. Endocrinol. Metab. 96, 1555-1559 (2011).
18. Anastasilakis, A. D. et al. The effect of teriparatide on serum Dickkopf 1 levels in postmenopausal women with established osteoporosis. Clin. Endocrinol. (Oxf.) 72, 752-757 (2010).
19. Eriksen, E. F. Cellular mechanisms of bone remodeling. Rev. Endocr. Metab. Disord. 11, 219-227 (2010).
20. Martin, T. J. & Sims, N. A. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol. Med. 11, 76-81 (2005). (Pubitemid 40193486)
21. Martin, T. J. et al. Mechanisms involved in skeletal anabolic therapies. Ann. NY Acad. Sci. 1068, 458-470 (2006). (Pubitemid 43824174)
22. Black, D. M. et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349, 1207-1215 (2003). (Pubitemid 37152030)
23. Finkelstein, J. S. et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. 349, 1216-1226 (2003). (Pubitemid 37152031)
24. Finkelstein, J. S., Wyland, J. J., Lee, H. & Neer, R. M. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 95, 1838-1845 (2010).
25. Dobnig, H. & Turner, R. T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136, 3632-3638 (1995).
26. Gasser, J., Ingold, P., Venturiere, A. & Green, J. Chronic subcutaneous, but not single intravenous dosing of rats with bisphosponates resuts in reduced bone anabolic response to PTH. J. Bone Miner. Res. 21 (Suppl. 1), S113 (2006).
27. Cosman, F. et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J. Bone Miner. Res. 26, 503-511 (2011).
28. File, E. & Deal, C. Clinical update on teriparatide. Curr. Rheumatol. Rep. 11, 169-176 (2009).
29. Lindsay, R. et al. Randomised controlled study of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on estrogen with osteoporosis. Lancet 350, 550-555 (1997). (Pubitemid 27348431)
30. Deal, C. et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6 month double-blind placebo-controlled trial. J. Bone Miner. Res. 20, 1905-1911 (2005). (Pubitemid 41532775)
31. Hodsman, A. B., Steer, B. M., Fraher, L. J. & Drost, D. J. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients. Bone Miner. 14, 67-83 (1991).
32. Dempster, D. W. et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J. Bone Miner. Res. 16, 1846-1853 (2001). (Pubitemid 32911491)
33. Lindsay, R. et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J. Bone Miner. Res. 21, 366-373 (2006).
34. Rubin, M. R. & Bilezikian, J. P. The anabolic effects of parathyroid hormone therapy. Clin. Geriatr. Med. 19, 415-432 (2003). (Pubitemid 36514527)
35. Jiang, Y. et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J. Bone Miner. Res. 18, 1932-1941 (2003). (Pubitemid 37377441)
36. Jilka, R. L. et al. Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone 44, 275-286 (2009).
37. Lindsay, R. et al. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J. Bone Miner. Res. 22, 495-502 (2007). (Pubitemid 47457425)
38. Satterwhite, J. et al. Pharmacokinetics of teriparatide (rhPTH[1-34]) and calciumpharmacodynamics in postmenopausal women with osteoporosis. Calcif. Tissue Int. 87, 485-492 (2010).
39. Verhaar, H. J. & Lems, W. F. PTH analogues and osteoporotic fractures. Expert Opin. Biol. Ther. 10, 1387-1394 (2010).
40. Chen, P. et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J. Bone Miner. Res. 20, 962-970 (2005). (Pubitemid 40712820)
41. Neer, R. M. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434-1441 (2001). (Pubitemid 32402100)
42. Greenspan, S. L. et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann. Intern. Med. 146, 326-339 (2007). (Pubitemid 351650593)
43. Miller, P. D. et al. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J. Clin. Endocrinol. Metab. 92, 3535-3541 (2007). (Pubitemid 47435332)
44. Inomata, N., Akiyama, M., Kubota, N. & Jüppner, H. Characterization of a novel parathyroid hormone (PTH) receptor with specificity for the carboxyl-terminal region of PTH (1-84). Endocrinology 136, 4732-4740 (1995).
45. Murray, T. M., Rao, L. G., Divieti, P. & Bringhurst, F. R. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligands. Endocr. Rev. 26, 78-113 (2005). (Pubitemid 40209388)
46. Orwoll, E. S. et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J. Bone Miner. Res. 18, 9-17 (2003). (Pubitemid 36008334)
47. Kaufman, J. M. et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos. Int. 16, 510-516 (2005).
48. Marcus, R., Wang, O., Satterwhite, J. & Mitlak, B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J. Bone Miner. Res. 18, 18-23 (2003). (Pubitemid 36008335)
49. Keaveny, T. M. et al. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J. Bone Miner. Res. 22, 149-157 (2007). (Pubitemid 46032608)
50. Nevitt, M. C. et al. Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos. Int. 17, 273-280 (2006). (Pubitemid 43053592)
51. Nevitt, M. C. et al. Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Osteoporos. Int. 17, 1630-1637 (2006). (Pubitemid 44477623)
52. Lyritis, G. et al. Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS. Curr. Med. Res. Opin. 26, 1799-1807 (2010).
53. Lindsay, R. et al. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporos. Int. 20, 943-948 (2009).
54. Cosman, F. et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J. Clin. Endocrinol. Metab. 95, 151-158 (2010).
55. Moen, M. D. & Scott, L. J. Recombinant full-length parathyroid hormone (1-84). Drugs 66, 2371-2381 (2006). (Pubitemid 46072448)
56. Zanchetta, J. R. et al. Treatment of postmenopausal women with osteoporosis with PTH(1-84) for 36 months: treatment extension study. Curr. Med. Res. Opin. 26, 2627-2633 (2010).
57. Verhaar, H. J. & Lems, W. F. PTH-analogs: comparable or different? Arch. Gerontol. Geriatr. 49, e130-e132 (2009).
58. Eastell, R. et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J. Bone Miner. Res. 24, 726-736 (2009).
59. Langdahl, B. L. et al. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif. Tissue Int. 85, 484-49v(2009).
60. Cosman, F. et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J. Bone Miner. Res. 16, 925-931 (2001). (Pubitemid 32332303)
61. Lindsay, R. et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch. Intern. Med. 164, 2024-2030 (2004). (Pubitemid 39390560)
62. Lane, N. E. et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J. Bone Miner. Res. 15, 944-951 (2000). (Pubitemid 30233419)
63. Kurland, E. S. et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos. Int. 15, 992-997 (2004). (Pubitemid 40064654)
64. Rittmaster, R. S. et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J. Clin. Endocrinol. Metab. 85, 2129-2134 (2000). (Pubitemid 32269232)
65. Black, D. M. et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N. Engl. J. Med. 353, 555-565 (2005). (Pubitemid 41138937)
66. Obermayer-Pietsch, B. M. et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J. Bone Miner. Res. 23, 1591-1600 (2008).
67. Boonen, S. et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 93, 852-860 (2008). (Pubitemid 351398563)
68. Cosman, F. et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N. Engl. J. Med. 353, 566-575 (2005). (Pubitemid 41138938)
69. Cosman, F., Nieves, J. W., Zion, M., Barbuto, N. & Lindsay, R. Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. J. Bone Miner. Res. 24, 1110-1115 (2009).
70. Finkelstein, J. S. et al. Effects of teriparatide retreatment in osteoporotic men and women. J. Clin. Endocrinol. Metab. 94, 2495-2501 (2009).
71. Miller, P. D. Safety of parathyroid hormone for the treatment of osteoporosis. Curr. crOsteoporos. Rep. 6, 12-16 (2008).
72. Vahle, J. L. et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol. Pathol. 30, 312-321 (2002). (Pubitemid 34556102)
73. Tashjian, A. H. Jr & Goltzman, D. On the interpretation of rat carcinogenicity studies for human PTH(1-34) and human PTH(1-84). J. Bone Miner. Res. 23, 803-811 (2008). (Pubitemid 351768798)
74. Jolette, J. et al. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2 year study in Fischer 344 rats. Toxicol. Pathol. 34, 929-940 (2006). (Pubitemid 46011145)
75. Harper, K. D., Krege, J. H., Marcus, R. & Mitlak, B. H. Osteosarcoma and teriparatide? J. Bone Miner. Res. 22, 334 (2007).
76. Subbiah, V., Madsen, V. S., Raymond, A. K., Benjamin, R. S. & Ludwig, J. A. Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos. Int. 21, 1041-1045 (2010).
77. Tashjian, A. H. Jr & Chabner, B. A. Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J. Bone Miner. Res. 17, 1151-1161 (2002). (Pubitemid 34680490)
78. Hodsman, A., Papaioannou, A. & Cranney, A. Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis. CMAJ 175, 48 (2006).
79. Hodsman, A. B. et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr. Rev. 26, 688-70v(2005).
80. van Staa, T. P. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif. Tissue Int. 79, 129-137 (2006). (Pubitemid 44440440)
81. Saag, K. G. et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 357, 2028-2039 (2007). (Pubitemid 350106710)
82. Saag, K. G. et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty six month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 60, 3346-3355 (2009).
83. Prince, R. et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J. Bone Miner. Res. 20, 1507-1513 (2005). (Pubitemid 41243539)